Please use this identifier to cite or link to this item:
|Title:||Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer|
|Authors:||QU C.f.; SONG E.; LI Y.; RIZVI S.m.a.; RAJA C.; ROSS R; APOSTOLIDIS CHRISTOS; ALLEN Barry J.|
|Citation:||CLINICAL & EXPERIMENTAL METASTASIS vol. 22 p. 575-586|
|Type:||Articles in periodicals and books|
|Abstract:||Purpose: The urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2). We have labeled PAI2 with 213Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy.|
|JRC Institute:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.